The Biostatistics Shared Resource provides support for the four broad major programmatic areas of YCC: clinical science;basic science;translational science and population science. It provides a highly interactive team of cancer biostatisticians who work collaboratively with basic, clinical, translational and population science researchers to advance the frontiers of cancer medicine and public health. The Biostatistics Shared Resource includes faculty in the Yale School of Public Health (YSPH) and staff who collaborate actively on a wide range of cancer clinical research projects and develop new methodologies related to these projects. The services provided by Biostatistics include: biostatistical support to research projects, assistance with the statistical and research aspects of new research projects and grant applications, data analysis, and training. As such, this core is vital to clinical trials/study design process. Additionally, this core has the major responsibility to support the protocol review and monitoring process of the YCC. Thus, this Shared Resource provides critical support for the complete spectrum of statistical services, from study design through the final research report writing. In January 2010, the Yale Center for Analytical Sciences (YCAS) was created in collaboration with the YSPH, Yale CTSA and Yale Cancer Center to bring all biostatistics under one umbrella. Dr. Peter Peduzzi was recruited to head the new center. Biostatistics is located with other components of YCAS, which was provided with new space 1 block from the Yale Cancer Center, Smilow Cancer Hospital and the YSPH. The co-location of Biostatistics within YCAS consolidates staff and resources for the more efficient design, conduct and analysis of cancer studies. Currently, the YCC supports partial effort for 3 faculty and 2 MS level biostatisticians. To meet anticipated demand engendered by need for YCC in investigator-initiated clinical research studies, bioinformatics, population based studies, we propose to expand this staff to include partial support for 3 additional faculty, 1 FTE additional PhD and .5 FTE in Bioinformatics support of which .3 faculty FTE and .5 staff FTE will be supported by the CCSG. In FY12, 32 YCC members from the 7 research programs accessed the Biostatistics Shared Resource, 13 of which hold peer-reviewed cancer-relevant funding. Of the nearly 4000 hours used, 22% went to protocol development (study design, sample size, analytic and monitoring plans) resulting in 14 grant submissions and 2 SPORE applications;data analysis accounted for 60% of the hours, resulting in 17 published manuscripts in 2012.
Well-designed, executed and analyzed studies are critical to advancing the treatment and care of people with cancer. Biostatistics plays a critical role in the design, analysis and interpretation of data from these studies that help to inform treatment and prevention strategies.
|Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326|
|Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083|
|Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291|
|Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40|
|Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631|
|Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025|
|Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461|
|Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853|
|Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573|
|Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331|
Showing the most recent 10 out of 675 publications